Provided by Tiger Trade Technology Pte. Ltd.

MannKind

5.78
+0.27004.90%
Post-market: 5.76-0.0232-0.40%19:59 EST
Volume:3.01M
Turnover:17.31M
Market Cap:1.77B
PE:59.05
High:5.86
Open:5.59
Low:5.53
Close:5.51
52wk High:6.51
52wk Low:3.38
Shares:307.07M
Float Shares:300.98M
Volume Ratio:0.70
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0979
EPS(LYR):0.1000
ROE:32.74%
ROA:9.95%
PB:-39.84
PE(LYR):57.80

Loading ...

MannKind Corporation Secures Five New U.S. Patents for FUROSCIX ReadyFlow Autoinjector

Reuters
·
Dec 23, 2025

MannKind Shares FUROSCIX® Business Updates

GlobeNewswire
·
Dec 23, 2025

MannKind CEO Michael Castagna Reports Disposal of Common Shares

Reuters
·
Dec 17, 2025

MannKind Corporation Issues Amendment on scPharmaceuticals Acquisition Filing

Reuters
·
Dec 16, 2025

MannKind (MNKD): Evaluating Valuation After FDA Acceptance of the FUROSCIX ReadyFlow Autoinjector sNDA

Simply Wall St.
·
Dec 15, 2025

MannKind Corp : Leerink Partners Raises Target Price to $9 From $7

THOMSON REUTERS
·
Dec 09, 2025

MannKind CEO Michael Castagna Reports Disposal of Common Shares

Reuters
·
Dec 05, 2025

BRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application (SNDA) Of Furoscix Readyflow™ Autoinjector

Reuters
·
Dec 01, 2025

MannKind Corp - Pdufa Target Action Date Set for July 26, 2026

THOMSON REUTERS
·
Dec 01, 2025

MannKind Announces U.S. FDA Accepts for Review Its Supplemental New Drug Application (Snda) of Furoscix Readyflow™ Autoinjector for the Treatment of Edema in Adults With Chronic Heart Failure or Chronic Kidney Disease

THOMSON REUTERS
·
Dec 01, 2025

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

GlobeNewswire
·
Dec 01, 2025

MannKind (MNKD) Is Up 6.4% After Wave of Analyst Upgrades Despite MNKD-101 Discontinuation – Has The Bull Case Changed?

Simply Wall St.
·
Nov 29, 2025

MannKind Initiated at Buy by Truist Securities

Dow Jones
·
Nov 25, 2025

What MannKind (MNKD)'s Phase 3 Trial Discontinuation Means for Pipeline Prospects and Shareholder Expectations

Simply Wall St.
·
Nov 19, 2025

MannKind (MNKD): Evaluating Valuation as Biotech Sector Dynamics Shift

Simply Wall St.
·
Nov 18, 2025

MannKind EVP Technical Operations Sanjay R. Singh Reports Sale of Common Shares

Reuters
·
Nov 15, 2025

MannKind to Present at the Jefferies Global Healthcare Conference

GlobeNewswire
·
Nov 12, 2025

MannKind Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Nov 11, 2025

Wedbush Cuts Price Target on MannKind to $10 From $11, Keeps Outperform Rating

MT Newswires Live
·
Nov 11, 2025

MannKind’s Strategic Advancements and Product Potential Justify Buy Rating Despite MNKD-101 Discontinuation

TIPRANKS
·
Nov 11, 2025